NASDAQ · SYRE
Spyre Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SYRE: Nov 3, 2026
Spyre Therapeutics, Inc. Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.79. The reported EPS for the same quarter last year was $-0.15.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.79 | $-0.67 | $-0.90 | 6 |
| Dec 2026 | $-0.81 | $-0.69 | $-0.93 | 6 |
| Mar 2027 | $-0.88 | $-0.80 | $-0.96 | 2 |
| Jun 2027 | $-0.85 | $-0.72 | $-0.98 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · Zacks · Barchart- BNK Invest · Oct 14, 10:47 AM EDTXBI, IOVA, SYRE, UTHR: ETF Inflow AlertLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $363.3 million dollar inflow — that's a 3.8% increase week
- RTTNews · Oct 6, 12:44 AM EDTSpyre Therapeutics Prices $350 Mln Public Offering Of Shares(RTTNews) – Spyre Therapeutics, Inc. (SYRE), a clinical-stage biotechnology company, announced the pricing of 4.11 million shares of its common stock at $85.00 per share. The offering is expected to raise approximately $350.0 million in gross proceeds.
- RTTNews · Sep 11, 12:06 PM EDTWeekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials(RTTNews) – Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.
- Zacks · Sep 9, 9:56 AM EDTSpyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis StudySYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.
- RTTNews · Sep 8, 8:39 AM EDTSpyre Therapeutics Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis(RTTNews) – Spyre Therapeutics, Inc. (SYRE) announced positive 12-week induction results from Part A of the Phase 2 SKYLINE trial evaluating SPY003, an investigational extended half-life anti-IL-23 antibody, in patients with moderately-to-severely active ulcerative colitis (UC).
- Zacks · Sep 3, 11:30 AM EDTSpyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- RTTNews · Aug 28, 10:42 AM EDTWeekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal(RTTNews) – This week's biotech landscape saw a wave of regulatory approvals across HIV, rare diseases, immunology, and diagnostics, alongside strategic licensing deals, manufacturing collaborations, and mixed clinical trial readouts.
- Barchart · Aug 27, 1:54 PM EDTStocks Finish Little Changed Ahead of Nvidia EarningsThe S&P 500 Index ($SPX ) (SPY ) closed down by -0.02% on Wednesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.05%. E-mini S&P futures (ESU26 ) rose +0.02%, and September E-mini…
- Barchart · Aug 26, 7:25 PM EDTStocks Slightly Higher on Mixed US Economic NewsThe S&P 500 Index ($SPX ) (SPY ) is up by +0.04% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.01%. E-mini S&P futures (ESU26 ) are up +0.03%, and September E-mini…
- Barchart · Aug 26, 6:10 PM EDTStocks Slip Ahead of Nvidia Earnings as Bond Yields RiseThe S&P 500 Index ($SPX ) (SPY ) is down by -0.02% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.10%. E-mini S&P futures (ESU26 ) are down -0.03%, and September E-mini…
- Zacks · Aug 26, 12:10 PM EDTSYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid ArthritisSpyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.
- RTTNews · Aug 26, 3:45 AM EDTSpyre's SPY072 Shows Mixed Efficacy In Phase 2 RA Study, Fails Internal Bar For Monotherapy(RTTNews) – Spyre Therapeutics (SYRE) announced topline results from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072, with both doses showing benefits on one or more efficacy endpoints. Meanwhile, the company said the magnitude of effe
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Spyre Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.